JP2023536008A5 - - Google Patents
Info
- Publication number
- JP2023536008A5 JP2023536008A5 JP2023523681A JP2023523681A JP2023536008A5 JP 2023536008 A5 JP2023536008 A5 JP 2023536008A5 JP 2023523681 A JP2023523681 A JP 2023523681A JP 2023523681 A JP2023523681 A JP 2023523681A JP 2023536008 A5 JP2023536008 A5 JP 2023536008A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- viral vector
- sequence identity
- pharmaceutical composition
- isolated cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2010009.5A GB202010009D0 (en) | 2020-06-30 | 2020-06-30 | Vector |
| GB2010009.5 | 2020-06-30 | ||
| PCT/GB2021/051668 WO2022003357A1 (en) | 2020-06-30 | 2021-06-30 | Vector |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536008A JP2023536008A (ja) | 2023-08-22 |
| JP2023536008A5 true JP2023536008A5 (enExample) | 2024-07-08 |
Family
ID=71949697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523681A Pending JP2023536008A (ja) | 2020-06-30 | 2021-06-30 | ベクター |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230175016A1 (enExample) |
| EP (1) | EP4172345A1 (enExample) |
| JP (1) | JP2023536008A (enExample) |
| KR (1) | KR20230056658A (enExample) |
| CN (1) | CN115997025A (enExample) |
| AU (1) | AU2021300616A1 (enExample) |
| BR (1) | BR112022026521A2 (enExample) |
| CA (1) | CA3183830A1 (enExample) |
| GB (1) | GB202010009D0 (enExample) |
| IL (1) | IL299505A (enExample) |
| MX (1) | MX2022016101A (enExample) |
| WO (1) | WO2022003357A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202003618D0 (en) | 2020-03-12 | 2020-04-29 | Univ Bristol | Gene Therapy |
| WO2021257480A2 (en) | 2020-06-14 | 2021-12-23 | Catalyst Biosciences, Inc. | Complement factor i-related compositions and methods |
| GB202217332D0 (en) * | 2022-11-18 | 2023-01-04 | Univ Bristol | Methods |
| EP4410988A1 (en) * | 2023-01-31 | 2024-08-07 | Universitätsklinikum Hamburg-Eppendorf | An aav2-vector variant for targeted transfer of genes |
| EP4669359A1 (en) * | 2023-02-21 | 2025-12-31 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | MAFB PROMOTER FOR GENE THERAPY FOR DIABETES |
| GB202304841D0 (en) * | 2023-03-31 | 2023-05-17 | Purespring Therapeutics Ltd | Promoter |
| CN121013858A (zh) * | 2023-04-27 | 2025-11-25 | 俄勒冈健康与科学大学 | 靶向肾脏的aav衣壳及其使用方法 |
| GB202414499D0 (en) * | 2024-10-02 | 2024-11-13 | Purespring Therapeutics Ltd | Methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| US20050169914A1 (en) * | 2003-08-01 | 2005-08-04 | Colgan Sean P. | Novel functions for decay accelerating factor (DAF) in inflammation |
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| EP2730282A1 (en) * | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| EP3795581A3 (en) * | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| EP3359663A4 (en) * | 2015-09-24 | 2019-08-14 | The Trustees of The University of Pennsylvania | COMPOSITION AND METHOD FOR THE TREATMENT OF A COMPLEMENT-MEDIATED DISEASE |
| US12653168B2 (en) * | 2018-09-13 | 2026-06-16 | Regeneron Pharmaceuticals, Inc. | Complement factor H gene knockout rat as a model of C3 glomerulopathy |
-
2020
- 2020-06-30 GB GBGB2010009.5A patent/GB202010009D0/en not_active Ceased
-
2021
- 2021-06-30 EP EP21748644.8A patent/EP4172345A1/en active Pending
- 2021-06-30 WO PCT/GB2021/051668 patent/WO2022003357A1/en not_active Ceased
- 2021-06-30 MX MX2022016101A patent/MX2022016101A/es unknown
- 2021-06-30 US US18/011,592 patent/US20230175016A1/en active Pending
- 2021-06-30 CN CN202180046691.7A patent/CN115997025A/zh active Pending
- 2021-06-30 KR KR1020237003243A patent/KR20230056658A/ko active Pending
- 2021-06-30 IL IL299505A patent/IL299505A/en unknown
- 2021-06-30 AU AU2021300616A patent/AU2021300616A1/en active Pending
- 2021-06-30 JP JP2023523681A patent/JP2023536008A/ja active Pending
- 2021-06-30 BR BR112022026521A patent/BR112022026521A2/pt unknown
- 2021-06-30 CA CA3183830A patent/CA3183830A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024054426A5 (enExample) | ||
| Bobbin et al. | RNA interference approaches for treatment of HIV-1 infection | |
| JP2025114562A (ja) | 非組み込みウイルス送達システムおよびその使用の方法 | |
| JP2025148444A (ja) | 未成熟終止コドン媒介障害を処置するための方法および組成物 | |
| JP2024095717A5 (enExample) | ||
| JP2018537984A5 (enExample) | ||
| JP7671483B2 (ja) | 癌の治療 | |
| JP2023534037A5 (enExample) | ||
| JP2022066336A5 (enExample) | ||
| CN115997025A (zh) | 载体 | |
| JP2020503265A5 (enExample) | ||
| JP2022501044A5 (enExample) | ||
| JP2023543125A5 (enExample) | ||
| IL262459B1 (en) | Compositions and methods for enhanced gene expression of pklr for treatment of pyruvate kinase deficiency | |
| WO2019213011A1 (en) | Compositions and methods for hemoglobin production | |
| JP2023537229A5 (enExample) | ||
| JP2020527167A5 (enExample) | ||
| JP2024527742A5 (enExample) | ||
| SI21122A (sl) | Uporaba sevov parapoksvirusa ovis za proizvodnjo antivirusnih zdravil in zdravil proti raku | |
| JP2023534293A5 (enExample) | ||
| JP2021500880A5 (enExample) | ||
| Kimchi-Sarfaty et al. | SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy | |
| Kurshakova et al. | The promise and pitfalls of AAV-mediated gene therapy for duchenne muscular dystrophy | |
| JP2025508987A5 (enExample) | ||
| Lu et al. | Gene therapy and cardiovascular diseases |